{"entity":{"id":"nct07862647","kind":"trial","name":"TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma","aka":[],"tldr":"A phase 1 trial of PoMA sonodynamic therapy run by Alpheus Medical, Inc., now recruiting.","summary":"TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma is a phase 1 interventional study registered as NCT07862647 by Alpheus Medical, Inc., with 30 participants planned, started 2026-10-29, primary completion expected 2027-10-30. Conditions recorded: Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM, Bihemispheric GBM, Glioblastoma. Interventions recorded: 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07862647","url":"https://clinicaltrials.gov/study/NCT07862647"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["poma-sonodynamic-therapy"],"companies":["alpheus-medical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07862647","phase":"1","setting":"A Phase 1 Clinical Trial Evaluating the Safety and Tolerability of Bilateral Hemispheric 5-ALA-Mediated Sonodynamic Therapy Using the LIDU System Before Standard Radiochemotherapy and During Adjuvant Temozolomide in Patients With Histologically Proven Newly Diagnosed Butterfly Glioma","sponsor":"Alpheus Medical, Inc.","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07862647/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"poma-sonodynamic-therapy","kind":"drug","name":"PoMA sonodynamic therapy","route":"/drugs/poma-sonodynamic-therapy/"}],"company":[{"id":"alpheus-medical","kind":"company","name":"Alpheus Medical","route":"/companies/alpheus-medical/"}]}}